Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

We present long-term follow-up of a dasatinib phase 3 study of patients with imatinib-resistant/-intolerant chronic myeloid leukemia (CML). In the CA180-034 study, 670 patients with imatinib-resistant/-intolerant CML in chronic phase (CML-CP) received dasatinib 100 mg once daily, 50 mg twice daily,...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Shah, Neil P., Guilhot, François, Cortes, Jorge E., Schiffer, Charles A., le Coutre, Philipp, Brümmendorf, Tim H., Kantarjian, Hagop M., Hochhaus, Andreas, Rousselot, Philippe, Mohamed, Hesham, Healey, Diane, Cunningham, Michael, Saglio, Giuseppe
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2014
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4915794/
https://ncbi.nlm.nih.gov/pubmed/24569263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-10-532341
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker